Literature DB >> 24456992

The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.

Lakshminarayanan Varadhan1, Tracy Humphreys2, Adrian B Walker3, George I Varughese4.   

Abstract

Rapid improvement in glycaemic control with GLP-1 receptor agonist (RA) therapy has been reported to be associated with significant progression of diabetic retinopathy. This deterioration is transient, and continuing GLP-1 RA treatment is associated with reversal of this phenomenon. Pre-existent maculopathy, higher grade of retinopathy and longer duration of diabetes may be risk factors for persistent deterioration.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  GLP-1 agonist; Retinopathy; Screening; Transient deterioration

Mesh：

Substances：

Year:  2014        PMID： 24456992     DOI： 10.1016/j.diabres.2013.12.041

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  9 in total

Review 1.  New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy.

Authors:  Mercy Saw; Vincent W Wong; I-Van Ho; Gerald Liew
Journal:  Eye (Lond)       Date:  2019-06-21       Impact factor: 3.775

Review 2.  Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.

Authors:  Gerhard H Scholz; Holger Fleischmann
Journal:  Ther Adv Endocrinol Metab       Date:  2014-10       Impact factor: 3.565

3.  Activation of retinal Müller cells in response to glucose variability.

Authors:  Fabiana Picconi; Mariacristina Parravano; Francesca Sciarretta; Chiara Fulci; Michela Nali; Simona Frontoni; Monica Varano; Anna Maria Caccuri
Journal:  Endocrine       Date:  2019-07-20       Impact factor: 3.633

Review 4.  The Impact of Bariatric Surgery on Diabetic Retinopathy: A Systematic Review and Meta-Analysis.

Authors:  Douglas Cheung; Noah J Switzer; David Ehmann; Christopher Rudnisky; Xinzhe Shi; Shahzeer Karmali
Journal:  Obes Surg       Date:  2015-09       Impact factor: 4.129

Review 5.  Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.

Authors:  Daiji Kawanami; Keiichiro Matoba; Kazunori Sango; Kazunori Utsunomiya
Journal:  Int J Mol Sci       Date:  2016-07-29       Impact factor: 5.923

6.  Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.

Authors:  Tina Vilsbøll; Stephen C Bain; Lawrence A Leiter; Ildiko Lingvay; David Matthews; Rafael Simó; Ida Carøe Helmark; Nelun Wijayasinghe; Michael Larsen
Journal:  Diabetes Obes Metab       Date:  2018-01-08       Impact factor: 6.577

Review 7.  Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review.

Authors:  Stephen C Bain; Michael A Klufas; Allen Ho; David R Matthews
Journal:  Diabetes Obes Metab       Date:  2018-10-15       Impact factor: 6.577

8.  Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.

Authors:  Gian Paolo Fadini; Mayur Sarangdhar; Angelo Avogaro
Journal:  BMJ Open Diabetes Res Care       Date:  2018-01-30

Review 9.  SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review.

Authors:  Christopher El Mouhayyar; Ruba Riachy; Abir Bou Khalil; Asaad Eid; Sami Azar
Journal:  Int J Endocrinol       Date:  2020-02-29       Impact factor: 3.257
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.